君实生物：9月29日召开董事会会议

Group 1 - The core point of the article is that Junshi Biosciences (SH 688180) held its 13th board meeting on September 29, 2025, to review proposals related to external investments and related transactions [1] - For the fiscal year 2024, Junshi Biosciences' revenue composition is 96.27% from the pharmaceutical manufacturing sector and 3.73% from other businesses [1] - As of the report, Junshi Biosciences has a market capitalization of 42.2 billion yuan [1] Group 2 - The article also highlights a competitive scenario in the beverage industry, where Nongfu Spring's new green bottle product has led to a significant decline in market share for Yibao, dropping nearly 5 percentage points [1]